The current breast cancer screening market is dominated by imaging technologies such as mammograms and ultrasound and is one of the few screening markets with broad government funding. The market size is limited by the technology in place (which is only effective with women aged 50-74 years) and the low level of compliance (due to fear of X-Rays and need to visit breast screening clinics). Although mammography has been shown be an effective screening tool, the accuracy of this technology has its limitations, and consequently 30% of mammography screening results will be made up of false negatives, false positives and indeterminate results.
In comparison to imaging technologies, BCAL test will be accessible to all women regardless of age and location. This is particularly advantageous for women between the age of 20 to 40 years who have no other effective screening method. As it is a blood-based test, BCAL is less invasive, with no exposure to x-rays, and fits in with standard laboratory blood collection and laboratory processing. BCAL will be a more cost effective and efficient business model than current imaging technologies – changing the model from multiple, high cost screening centers to a centralized cost effective laboratory process. This will reduce healthcare costs, increase user compliance and clinical outcomes.